Drug Trial Radar · NCT07148414
A Study of SPY072 in Rheumatic Disease
Last checked: Nov 19, 2026Latest source record: Jun 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
285
Planned (sponsor's estimate)
Start
Aug 21, 2025
Primary completion
Oct 31, 2026
Study completion Mar 31, 2028
Sponsor
- Lead sponsor
- Spyre Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, double-blind, placebo-controlled, Phase 2, proof-of-concept basket study with the goal of assessing the efficacy and safety of SPY072 compared to placebo in adults (aged ≥18 years) with rheumatic disease (RD).
Conditions
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Axial Spondyloarthritis
- Rheumatic Diseases
- Rheumatic Joint Disease
- PsA (Psoriatic Arthritis)
- AxSpA
- Rheumatologic Disease
Interventions
SPY002-072Drug
Experimental
PlaceboDrug
Matching Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rheumatoid Arthritis: Change from baseline in Disease Activity Score in 28 joints (c-reactive protein) (DAS-CRP)Time frame: Week 12
- Axial Spondyloarthritis: Change from baseline in Ankylosing Spondylitis Disease Activity Score (ADAS)Time frame: Week 16
- Psoriatic Arthritis: Proportion of participants who achieve an American College of Rheumatology 20 Response Criteria (ACR20) responseTime frame: Week 16
Locations
64 sites in 8 countries. Site status is shown where the registry gives one.
Site 113
Avondale, Arizona
Site 118
Tucson, Arizona
Site 114
Chula Vista, California
Site 111
Covina, California
Site 108
Tujunga, California
Site 112
Upland, California
Site 107
Whittier, California
Site 115
Aventura, Florida
Site 109
Hialeah, Florida
Site 106
Ormond Beach, Florida
Site 110
Tampa, Florida
Site 116
Willowbrook, Illinois
Site 119
Rockville, Maryland
Site 104
Duncansville, Pennsylvania
Site 105
Corpus Christi, Texas
Site 120
Irving, Texas
Site 103
Tomball, Texas
Site 102
Tomball, Texas
Site 503
Lovech, Lovech, Bulgaria
Site 502
Pleven, Pleven, Bulgaria
Site 506
Plovdiv, Plovdiv, Bulgaria
Site 505
Plovdiv, Plovdiv, Bulgaria
Site 504
Varna, Varna, Bulgaria
Site 706
Hlučín, Hlučín, Czechia
Site 702
Moravská Ostrava, Ostrava-město, Czechia
Site 704
Pardubice, Pardubice Region, Czechia
Site 705
Prague, Praha, Hlavní Mesto, Czechia
Site 703
Prague, Praha, Hlavní Mesto, Czechia
Site 701
Uherské Hradiště, Zlín, Czechia
Site 308
Batumi, Georgia
Site 302
Kutaisi, Georgia
Site 306
Tbilisi, Georgia
Site 303
Tbilisi, K'alak'i T'bilisi, Georgia
Site 304
Tbilisi, K'alak'i T'bilisi, Georgia
Site 301
Tbilisi, K'alak'i T'bilisi, Georgia
Site 307
Tbilisi, K'alak'i T'bilisi, Georgia
Site 305
Tbilisi, K'alak'i T'bilisi, Georgia
Site 201
Chisinau, Moldova
Site 202
Chisinau, Moldova
Site 401
Krakow, Lesser Poland Voivodeship, Poland
Showing 40 of 64 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.